Kalyani Kottilil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kalyani Kottilil has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jessica A. Regan
Duke Molecular Physiology Institute, Duke University School of Medicine
2 shared publications - Lydia Coulter Kwee
Duke Molecular Physiology Institute, Duke University School of Medicine
2 shared publications - Svati H. Shah
Duke University School of Medicine
2 shared publications - Adrian F. Hernandez
Duke University School of Medicine, Durham, North Carolina, USA
1 shared publication - Danielle Chiang
Scripps Research Translational Institute, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, United States, 1 858-784-1000
1 shared publication - Edward Ramos
Scripps Research Institute, La Jolla, CA, United States
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 15 (1) , e80263
COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study
Background: Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19. Objective: The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR. Methods: This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency. Results: Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%; P <.001) and symptom rebound (NPR: 47.7%, 95% CI 36.1%-60.8% vs control: 16.9%, 95% CI 10.9%-25.7%; P <.001) was higher in the NPR group than the control group. Conclusions: This study demonstrates that while COVID-19 rebound occurs in both NPR-treated and untreated outpatients, the incidence is higher in the NPR group.
- 2 June 2026
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 15 (1) , e80263
Open AccessCOVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study
Background: Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19. Objective: The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR. Methods: This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency. Results: Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%; P <.001) and symptom rebound (NPR: 47.7%, 95% CI 36.1%-60.8% vs control: 16.9%, 95% CI 10.9%-25.7%; P <.001) was higher in the NPR group than the control group. Conclusions: This study demonstrates that while COVID-19 rebound occurs in both NPR-treated and untreated outpatients, the incidence is higher in the NPR group.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (5) , e005073
CARS2 Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health Substudy
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (5) , e005073
CARS2 Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health Substudy
- Open Access
Comprehensive Comparison of a Genotype-Forward vs. Phenotype-Forward Approach for Monogenic Cardiovascular Diseases in the UK Biobank Cohort
Background Monogenic cardiovascular diseases (MCVD) remain substantially under-diagnosed, and thus interest is shifting from a phenotype-forward approach towards a genotype-first strategy that applies to population-wide genomic screening. We evaluated the prevalence of pathogenic and predicted pathogenic MCVD variants and assessed disease expression in the population-based UK Biobank (UKB) cohort to determine whether yield is greater in phenotype-versus genotype-forward approach. Methods Pathogenic and likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) predicted to be pathogenic (pp-VUS) in 47 MCVD genes were assessed. In the genotype-forward approach, UKB participants with P/LPs or pp-VUS were assessed for symptoms of disease using electronic health record (EHR) interrogation, emulating a clinical approach to population-based screening. In the phenotype-forward approach, participants with stricter EHR-based evidence of disease expression were identified (emulating current clinical care) and the presence of P/LPs and pp-VUS was determined. Results Following QC, 467,850 participants were included. Overall, 1 in 125 participants in UKB carry an MCVD P/LP. In the genotype-forward approach, 3,709 (0.79%) participants carried an MCVD P/LP and 42.1% of these had symptoms of the associated MCVD; another 29,269 (6.3%) carried a pp-VUS with 21.5% of these having symptoms of disease. In the phenotype-forward approach, 62,488 (13.4%) expressed an MCVD using strict evidence of disease expression and of these individuals 1% carried an associated P/LP variant and 2.4% carried an associated pp-VUS. Conclusion We show here that a genotype-forward approach leads to a 2.5 times higher diagnostic yield (3.6 times higher when considering pp-VUS) compared with the phenotype-forward approach, which missed 936 P/LP carriers with disease symptoms. While cost, access and ethics need to be considered, these results support expanded population-based genetic screening to improve diagnosis of potentially treatable MCVD.
Open AccessComprehensive Comparison of a Genotype-Forward vs. Phenotype-Forward Approach for Monogenic Cardiovascular Diseases in the UK Biobank Cohort
Background Monogenic cardiovascular diseases (MCVD) remain substantially under-diagnosed, and thus interest is shifting from a phenotype-forward approach towards a genotype-first strategy that applies to population-wide genomic screening. We evaluated the prevalence of pathogenic and predicted pathogenic MCVD variants and assessed disease expression in the population-based UK Biobank (UKB) cohort to determine whether yield is greater in phenotype-versus genotype-forward approach. Methods Pathogenic and likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) predicted to be pathogenic (pp-VUS) in 47 MCVD genes were assessed. In the genotype-forward approach, UKB participants with P/LPs or pp-VUS were assessed for symptoms of disease using electronic health record (EHR) interrogation, emulating a clinical approach to population-based screening. In the phenotype-forward approach, participants with stricter EHR-based evidence of disease expression were identified (emulating current clinical care) and the presence of P/LPs and pp-VUS was determined. Results Following QC, 467,850 participants were included. Overall, 1 in 125 participants in UKB carry an MCVD P/LP. In the genotype-forward approach, 3,709 (0.79%) participants carried an MCVD P/LP and 42.1% of these had symptoms of the associated MCVD; another 29,269 (6.3%) carried a pp-VUS with 21.5% of these having symptoms of disease. In the phenotype-forward approach, 62,488 (13.4%) expressed an MCVD using strict evidence of disease expression and of these individuals 1% carried an associated P/LP variant and 2.4% carried an associated pp-VUS. Conclusion We show here that a genotype-forward approach leads to a 2.5 times higher diagnostic yield (3.6 times higher when considering pp-VUS) compared with the phenotype-forward approach, which missed 936 P/LP carriers with disease symptoms. While cost, access and ethics need to be considered, these results support expanded population-based genetic screening to improve diagnosis of potentially treatable MCVD.